January 16, 2025
Article
Since 1968, CR&T is proud to have maintained our mission to fund research emphasizing the cause, prevention, treatment and cure of MPN.
FDA Approves Lumakras with Vectibix in KRAS G12C+ Colorectal Cancer
FDA Approves Calquence Combo for Mantle Cell Lymphoma
An Expert Breaks Down the Meaning of MRD Testing in Cancer Care
Expanding CR&T's Impact